ReviewNature reviews. Disease primers2025
Bacterial vaginosis.
Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of menstrual cups on vaginal health, reproductive tract and urogenital infections: a systematic review and meta-analysis.EBioMedicine · 2026Pooled it
- Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial.Cell host & microbe · 2026Trial
- Vaginal Ecosystem During Gestation and Puerperium: Microbiota, Dysbiosis, Infection and Fetal-Maternal Implications.Microorganisms · 2026Review
- Metabolic cooperation supports mutual growth between the protozoan parasite Trichomonas vaginalis and dysbiotic vaginal bacteria.PLoS pathogens · 2026Article
- Predicting bacterial vaginosis incidence using artificial neural networks.PLoS computational biology · 2026Article
- The cervicovaginal microbiome: an emerging determinant of HPV infection and disease.Journal of virology · 2026Review
- Review
- Article
- The Impact of the Vaginal Microbiome and Microbial Metabolites on HIV Transmission at the Female Reproductive Tract Epithelial Barrier.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Transkingdom interactions between HPV and the microbiome in the female reproductive tract: Gaps, challenges, and emerging perspectives.PLoS pathogens · 2026Article
- Mechanisms of the Oral-Gut Microbiota Axis in Adverse Pregnancy Outcomes.Microorganisms · 2026Review
- Prospective study of vaginal samples for the detection ofMicrobiology spectrum · 2026Article
- Article
- Review
- Underexplored maternal microbiomes: immune, metabolic, and microbial pathways shaping pregnancy outcomes.Infection and immunity · 2026Review
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- Regulatory Effects ofMicroorganisms · 2026Article
- Bacterial vaginosis male partner treatment in the United States.American journal of obstetrics and gynecology · 2026Article
- The cost-effectiveness of male-partner treatment to prevent recurrence of bacterial vaginosis.Scientific reports · 2026Article
- Spatial organization ofInfection and immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial vaginosis (BV) is a vaginal microbiome disorder that is associated with preterm birth and spontaneous abortion, increased risk of HIV infection and sexually transmitted infections, and has negative effects on quality of life. BV affects one in four women globally, with the highest burden in resource-limited settings. Marked alterations in vaginal microbiome composition, in pro-inflammatory cytokines and chemokines, and in the proteome and metabolome characterize BV and contribute to adverse sequelae. Despite its prevalence, the exact aetiologic agent of BV is unknown and its pathophysiology is poorly understood. These knowledge gaps impede diagnostic and management approaches, with recommended treatment strategies resulting in recurrence that exceeds 50% over 3-6 months. New data on the sexual transmission of BV, including evidence that male-partner treatment improves cure, have improved our understanding of its aetiology and pathogenesis, and provide opportunities for developing optimal diagnostic, treatment and prevention strategies. Other factors probably also contribute to the low efficacy of current treatments, including biofilm and/or antimicrobial resistance, and failure to recolonize a favourable vaginal microbiome after treatment. The complex pathophysiology of BV highlights that individualized and multifaceted management approaches will be required to manage the refractory and adverse sequelae of BV.
Indexed as
Identifiers
40537474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.